We are live on ! Find out more
NRD

Nebula Research & Development Portfolio holdings

AUM $1.17B
1-Year Est. Return 15.19%
This Fund
S&P 500
This Quarter Est. Return
+7.19%
1 Year Est. Return
+15.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$836M
AUM Growth
+$219M
Cap. Flow
+$188M
Cap. Flow %
22.5%
Top 10 Hldgs %
4.49%
Holding
1,220
New
441
Increased
247
Reduced
213
Closed
319

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.41M
2
AAP icon
Advance Auto Parts
AAP
+$4.15M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.96M
4
DLTR icon
Dollar Tree
DLTR
+$3.82M
5
MSFT icon
Microsoft
MSFT
+$3.74M

Top Sells

Rank Stock Value
1
BAC icon
Bank of America
BAC
+$2.82M
2
KO icon
Coca-Cola
KO
+$2.82M
3
GD icon
General Dynamics
GD
+$2.82M
4
ORCL icon
Oracle
ORCL
+$2.81M
5
HLNE icon
Hamilton Lane
HLNE
+$2.8M

Sector Composition

Rank Sector Weight
1 Technology 16.51%
2 Industrials 15.72%
3 Consumer Discretionary 15.68%
4 Healthcare 13.43%
5 Financials 10.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SEB icon
401
Seaboard Corp
SEB
$4.37B
$778K 0.09%
248
-146
-37% -$456K
ROL icon
402
Rollins
ROL
$18.7B
$776K 0.09%
15,341
-3,674
-19% -$181K
ENOV icon
403
Enovis
ENOV
$1.67B
$774K 0.09%
17,982
+10,073
+127% +$449K
VLTO icon
404
Veralto
VLTO
$24B
$770K 0.09%
6,888
-19,736
-74% -$2.09M
ALEX
405
DELISTED
Alexander & Baldwin
ALEX
$770K 0.09%
40,116
-6,269
-14% -$118K
CMPR icon
406
Cimpress
CMPR
$2.41B
$768K 0.09%
9,378
+1,128
+14% +$100K
ANIP icon
407
ANI Pharmaceuticals
ANIP
$1.82B
$766K 0.09%
12,844
+7,211
+128% +$440K
AVPT icon
408
AvePoint
AVPT
$2.79B
$764K 0.09%
+64,878
New +$711K
ATRC icon
409
AtriCure
ATRC
$1.98B
$759K 0.09%
27,066
-27,301
-50% -$673K
OTEX icon
410
Open Text
OTEX
$5.98B
$758K 0.09%
+22,785
New +$718K
TNET icon
411
TriNet
TNET
$3.13B
$757K 0.09%
+7,811
New +$778K
LEVI icon
412
Levi Strauss
LEVI
$9.71B
$757K 0.09%
34,730
+17,845
+106% +$338K
EWCZ
413
DELISTED
European Wax Center
EWCZ
$757K 0.09%
+111,261
New +$863K
NOW icon
414
ServiceNow
NOW
$115B
$755K 0.09%
+4,220
New +$694K
MRSH
415
Marsh
MRSH
$90.8B
$755K 0.09%
+3,383
New +$751K
WHD icon
416
Cactus
WHD
$3.69B
$754K 0.09%
12,638
-8,248
-39% -$479K
VREX icon
417
Varex Imaging
VREX
$472M
$753K 0.09%
+63,151
New +$804K
MAX icon
418
MediaAlpha
MAX
$746M
$746K 0.09%
+41,212
New +$657K
STLD icon
419
Steel Dynamics
STLD
$37.1B
$744K 0.09%
+5,902
New +$717K
VRTS icon
420
Virtus Investment Partners
VRTS
$1.15B
$744K 0.09%
3,551
+1,942
+121% +$416K
RCI icon
421
Rogers Communications
RCI
$18.5B
$741K 0.09%
+18,417
New +$721K
KRC icon
422
Kilroy Realty
KRC
$4.47B
$739K 0.09%
19,104
-17,465
-48% -$617K
TTEK icon
423
Tetra Tech
TTEK
$8.62B
$737K 0.09%
+15,626
New +$695K
MFC icon
424
Manulife Financial
MFC
$74.2B
$736K 0.09%
+24,916
New +$669K
PAAS icon
425
Pan American Silver
PAAS
$18.2B
$735K 0.09%
+35,201
New +$742K
15 16
17
18 19

Similar funds

SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
HIP
HPS Investment Partners New York $1.52B AUM 19.81% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return

Nebula Research & Development's Q3 2024 Portfolio in Review

As of Q3 2024, Nebula Research & Development held 1,220 positions worth $836M, up 35% from $618M the previous quarter. Its ten largest holdings account for 4.5% of the portfolio.

Nebula Research & Development deployed $188M of net new capital in Q3 2024, opening 441 new positions and adding to 247 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 52,699 shares worth $3.7M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was Travelers Companies, an estimated $2.39M trimmed.

  • Nebula Research & Development's largest Q3 2024 buy was BioMarin Pharmaceuticals: 52,699 shares worth $3.7M.
  • Nebula Research & Development added most to Dollar Tree in Q3 2024, an estimated $3.82M increase.
  • Nebula Research & Development's biggest Q3 2024 reduction was Travelers Companies, cutting an estimated $2.39M.
  • Nebula Research & Development fully exited Bank of America in Q3 2024, selling an estimated $2.82M.
  • Nebula Research & Development's ten largest holdings make up 4.5% of its $836M portfolio in Q3 2024.
  • Nebula Research & Development opened 441 new positions and closed 319 in Q3 2024.
  • Nebula Research & Development's portfolio value rose 35% quarter-over-quarter to $836M.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.